Get In Touch

Cancer has been a growing concern affecting more than eight million people across the globe. Statistics published by the World Health Organization stated that more than 60% of cancer cases occur in Africa, Asia, and South and Central America. The organization also projected that the number of cancer cases could reach 22 million by 2032. Lung, liver, stomach, colorectal, and breast are among the leading cause of cancer deaths. The high mortality rate and wide prevalence of cancer have driven scientists to engage in the discovery of better treatment options of the disease. Alkylating agents were among the earliest classes of drugs available for treating cancer. These are the first nonhormonal drugs successfully used in the cancer treatment. Traditionally, alkylating agents are grouped into SN1 and SN2 types. The SN1 agents directly react with biological molecules. The SN2 type agents are those that form an intermediate, which then react with the biological molecules. Alkylating agents act by damaging the DNA strands and prevent cancer cells from replicating. These agents show activity against the cancer cell during each phase of its life cycle, thus making alkylating agents desirable for treating a wide range of cancers. As alkylating agents act by altering the DNA strands, prolonged use of about 5 years to 10 years of these agents can lead to bone marrow damage, and, in rare instances, it might lead to acute leukemia. Temodar (temozolomide) by Merck, Treanda (bendamustine) by Teva Pharma, and Eloxatin (Oxaliplatin) by Sanofi are the major drugs in this class. Temodar and Eloxatin lost their exclusivity in 2013 and 2012, respectively.

The rising prevalence of different cancer types such as lymphoma, carcinoma, leukemia, and bladder cancer is a major growth driver for the global alkylating agents market. Sedentary and unhealthy lifestyles and environmental changes are factors leading to the increasing prevalence of cancer. Alkylating agents are used in chemotherapy for 100 different cancer types known till date. In addition, rising awareness about various forms of cancers and their treatment is one of the key factors for the growth of the global alkylating agents market.

The global alkylating agents market has been segmented based on type, route of administration, distribution channel, and region. In terms of type, the market is segmented into five major classes: nitrogen mustards, alkyl sulfonates, nitrosoureas, triazines, and ethylenimines. The dosage and schedule of each type of alkylating agent depend on the patient’s overall health, weight and cancer type which is to be treated. Nitrogen mustards include drugs such as mechlorethamine, ifosfamide, melphalan, chlorambucil, and cyclophosphamide. Nitrosoureas class of alkylating agents consists drugs such as streptozocin, carmustine, and lomustine. Alkyl sulfonates include drugs such as busulfan, treosulfan, and mannosulfan. Ethylenimines include drugs such as thiotepa and altretamine. Triazenes include drugs such as dacarbazine and temozolomide. In terms of route of administration, the market is segmented into oral route and intravenous route. In terms of distribution channel, the market is divided into hospital pharmacies, retail pharmacies, online retailers, and private clinics.

Geographically, the global alkylating agents market is segmented into five key regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounts for the largest market share owing to high research and development, favorable reimbursement policies, and availability of advanced health care infrastructure. The implementation of the Affordable Care Act has significantly posed limitations to hospitals as well as pharmaceutical companies with respect to costing of new drugs. Europe is the second largest market globally due to the presence of high quality scientific companies and research organizations. However, lack of proper reimbursement policies and regulatory framework pertaining to new drug development are key restraints which might hamper the market growth in Europe.

Key players operating in the global alkylating agents market include Merck & Co., Inc., Cipla Inc., and Pfizer Inc.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Alkylating Agents Market

Pre Book